This document summarizes information about Probuphine, an implantable formulation for the treatment of opioid dependency. Probuphine consists of 4 subdermal rods containing buprenorphine, which is released over 6 months. It has advantages over other treatments as it only requires insertion every 6 months by a skilled professional and maintains consistent drug levels to support recovery. Common side effects include pain or swelling at the implant site. The implants aim to provide long term treatment for opioid addiction through this convenient dosage form.

1. Probuphine for treatment of opioid dependency
Presented By:
GOLAP Sk.
Roll no:- 19301913032
Reg no:- 131930210032
4th Year, Semester: 7th
Bengal School Of Technology, (A college of Pharmacy)
Hooghly ,West Bengal
2016

2. OPOID DEPENDENCY
Opioid dependency is a medical condition
that is characterized by the compulsive use
of opioids.
Opioids include substances:
 Morphine
Heroin
Codeine
Oxycodone

3. TYPES OF DOSAGE FORM
AVAILABLE
Tablet Petazocine 5 mg tab
Injection Naloxone 0.4-0.8 mg inj
Sublingual Buprenorphine 0.2-0.4 mg subli
Implant Buprenorphine 74.2 mg

4. Implants are the drug delivery systems which act
as reservoir of loaded drug and deliver it over a
period of time in a controlled manner upon
insertion into the body.
 INTRAMUSCULAR
 INTRACARNIAL
 SUBDERMAL

5. Probuphine
(buprenorphine; ethylene vinyl acetate)
Implantable formulation of buprenorphine
Properties of Individual Rods
• 80 mg BPN & ethylene vinyl acetate
• 26mm long & 2.5mm diameter rod
• Sustained release up to 6 month

6. General instruction:
Each dose consist of 4 implants inserted subdermally in the inner side of
the upper arm. Implant are intended to be in place for 6 month &
Removes implants by the end of the 6 month.
Dose & strengths:
Probuphine is a sterile ,single, off white ,soft, flexible ,rod shape
ethylene vinyl acetate[EVA] implant .74.2mg probuphine.

7. *

8. Mechanism of Action:
PROBUPHINE implants contain buprenorphine.
Buprenorphine is a partial agonist at the mu
opioid receptor and an antagonist at the kappa-
opioid receptor.

9. ADVERSE REACTIONS
Implant site pain
Headache
Constipation
Back pain
Allergic reaction
Vomiting
Infection at implant site

10. Long term treatment
One time invest
Very effective as
rehabitation
 Best choice for drug
addicted persons
 Potential selected
chronic diseases with
low dose
Costly
Skilled personnel required
For insertion & removal
Pain, irritation, swelling
Implant comes out by itself

11. Reference:
1. Breasted JG. Ancient Records of Egypt. University of Chicago Oriental Institute Publications, Vol. III, P.
217. University of Chicago Press, 1930.
Kiang TK, Epsom MH, Chang TK. UDP glucuronos yltransferase and clinical drug-drug interactions.
Pharmaco There 2005; 106:97-132
Behar, K.L., et al., 1999. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of
alcohol-dependent and hepatic encephalopathy patients. American Journal of Psychiatry 156(6):952-954
Breiter, H.C., et al., 1997. Acute effects of cocaine on human brain activity and emotion. Neuron 19(3):591-
611
Judd, L.L., et al., 1998. Effective medical treatment of opiate addiction. Journal of the American Medical
Association 280(22):1936-1943
 Ling W, Mooney L, Zhao M, et al. Selective review and commentary on emerging pharmacotherapies
 Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: Randomized
comparison to placebo and sublingual buprenorphine/ naloxone. Addiction, 2013;108(12
 ECRI Institute. AHRQ Healthcare Horizon Scanning System Potential High-Impact Interventions: Priority
Area 14: Substance Abuse. Prepared by ECRI Institute for AHRQ under Contract No.
HHSA290201000006C. Rockville, MD: Agency for Healthcare Research and Quality; December 2013
1. Rosenthal RN, Lowell MR, Kim S, et al. Effect of Buprenorphine Implants on Illicit Opioid Use Among
Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized
Clinical Trial. JAMA. 2016;19:282-290.
Braeburn Pharma. Probuphine (buprenorphine) implant for sub dermal administration.
Prescribing Information. Reference ID: 3937415. Princeton, NJ: Braeburn Pharma; revised
May 2016.